Clinical Trial Search

Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants

Primary: Influence of Pre- and Post- Incentives on Participation Rates. — 4; 6; 15; 69 Participants

Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants

Primary: Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms…

Primary: Feasibility: Percentage of Patients Entering Any Exercise Data Into the Mobile App ≥50% of the Study Period Days, Excluding Hospitalization — 18; 14 Participants

Primary: Number of Participants With Hematological Response, as Measured by Any One or More of the Following Response Assessments: IWG-MDS and IWG-MF Criteria as Accurate and…

Primary: Number of Adverse Events — 250; 119; 24; 0 events

Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants

Primary: Number of [68Ga]Ga-DOTA-TATE Positive Participants (TP Participants) Among CIM Positive Participants (TP or FN Participants) — 40; 6 Participants

Primary: 12-Month Progression-Free Survival (PFS) — 0.44 probability

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: The Diagnostic Sensitivity of PET/CT for Detection of Lymph Node Metastasis in Abdomen — 50; 65 percentage of participants

Primary: Recruitment Rate (Percentage of Potentially Eligible Participants Who Were Enrolled to the Study) — 20.3 percentage of participants

Primary: Tumor Response — 0; 1; 12; 11 participants

Primary: Percentage of Patients Alive and Free of Progression at 12 Weeks (PFS12) — 52.6; 57.9 percentage of patients